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Abstract: The aim of this work was to assess the impact on measurements of methylation 
of a panel of four cancer gene promoters of purifying tumor cells from colorectal tissue 
samples using the epithelial cell adhesion molecule (EpCAM)-immunomagnetic cell 
enrichment approach. We observed that, on average, methylation levels were higher in 
enriched cell fractions than in the whole tissue, but the difference was significant only for 
one out of four studied genes. In addition, there were strong correlations between 
methylation values for individual samples of whole tissue and the corresponding enriched 
cell fractions. Therefore, assays on whole tissue are likely to provide reliable estimates of 
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tumor-specific methylation of cancer genes. However, tumor cell tissue separation using 
immunomagnetic beads could, in some cases, give a more accurate value of gene promoter 
methylation than the analysis of the whole cancer tissue, although relatively expensive and 
time-consuming. The efficacy and feasibility of the immunomagnetic cell sorting for 
methylation studies are discussed. 
Keywords: DNA methylation; epigenetics; epithelial cell adhesion molecule (EpCAM); 
immunomagnetic enrichment; colon cancer; pyrosequencing 
 
1. Introduction 
It is now widely accepted that cancer is a multi-step process resulting from the accumulation of 
both genetic and epigenetic alterations of the genome [1]. Gene mutations and epigenetic 
modifications were viewed initially as separate aetiological mechanisms for carcinogenesis but recent 
evidence points to crosstalk between these two mechanisms. Gene mutations may disrupt several 
epigenetic patterns and epigenetic modifications can drive genome instability and mutagenesis [2,3].  
Colorectal cancer (CRC) is one of the commonest human cancers with over one million new cases 
diagnosed worldwide annually [4]. Most CRC cases (75%–80%) occur sporadically as a result of the 
accumulation of both mutations and epigenetic modifications of several genes [5], and large-scale 
DNA methylation studies suggest that CRC can be divided into at least three subtypes according to the 
patterns of DNA methylation and of mutations in key CRC genes [6,7]. 
DNA methylation involves covalent addition of methyl groups to the 5' position on cytosine 
residues, usually in cytosine-phosphate-guanine (CpG) dinucleotides, and is one of the most studied 
epigenetic marks in CRC [8]. Methylation of CpG islands (domains unusually enriched with CpG 
dinucleotides) in the promoter region of a gene can induce chromatin conformational modifications 
and inhibit the access of the transcriptional machinery, thus altering gene expression levels. Promoter 
hypermethylation is commonly associated with gene silencing and promoter demethylation with gene 
expression. The ever-growing number of genes that show epigenetic alterations in cancer emphasizes 
the crucial role of these epigenetic alterations, and particularly of DNA methylation, for future 
diagnosis, prognosis and prediction of response to therapies [9]. Therefore, active research is currently 
ongoing to develop rapid, cost effective and reproducible tools for the detection of epigenetic  
marks [9]. Most of the currently available techniques are based on DNA analysis following sodium 
bisulfite treatment that converts unmethylated cytosines to uraciles, leaving methylated cytosines 
unchanged. At present, pyrosequencing of bisulfite treated DNA is considered as a gold standard 
technique for the quantification of DNA methylation [10]. There is now good evidence of differential 
DNA methylation patterns between normal cells in tissues and cancerous cells in equivalent  
tissues [11]. Human solid tumors are characterized by phenotypically heterogeneous populations of 
both normal and malignant cells, with varying degrees of differentiation and tumor initiating potential. 
Therefore, investigation of DNA methylation patterns in samples containing such mixed tissue might 
be confounded due to the presence of normal cells with different methylation patterns.  
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The epithelial cell adhesion molecule (EpCAM; CD326) is a transmembrane glycoprotein, highly 
overexpressed on most carcinomas, and its downregulation inhibits the oncogenic potential of multiple 
tumor types [12]. EpCAM is expressed at a high level and frequency in colon cancer tissues (in 97%) 
and in most human adenocarcinomas [13–15]. Recently, EpCAM has become of interest because it is a 
signal transducer [12,16], and a potential marker of cancer-initiating cells [17] whose role in the 
development of cancer and in tumor progression depends on the tumor type [12]. In certain tumor 
types, EpCAM overexpression is linked to advanced stage of disease and worse overall survival, 
suggesting that EpCAM may have utility as a potential prognostic marker [18]. 
In the present study, we aimed to compare the methylation profiles of DNA extracted from an 
EpCAM-enriched cell fraction and from non-enriched CRC cells (whole tumor DNA) to determine 
whether such cellular enrichment with tumor cells would increase the sensibility of the results. For this 
purpose, we quantified DNA methylation profiles of four CRC-related genes (APC, MGMT, hMLH1, 
CDKN2A/p16) in DNA obtained from human CRC tissues. 
2. Results and Discussion 
2.1. Results 
2.1.1. Patient Characteristics 
The study included 24 patients with primary colorectal adenocarcinoma. Median age of CRC 
patients was 73 years (range 47–91) with 10 females and 14 males. Five of 24 patients presented with 
metastatic disease to the liver and were classified as TNM stage IV; 6 patients were TNM stage III,  
9 and 4 patients were TNM stages II and I, respectively. The characteristics of the patients are 
summarized in Table 1. 
Table 1. Patient and tumor characteristics. 
Characteristic No. of patients  Characteristic No. of patients 
Age (range years)   Primary tumor site  
≤50 (47–50) 3  Colon dx 15 
51–69 (53–65) 5  Colon sx 9 
70–79 (70–76) 5  Tumor differentiation  
≥80 (81–91) 11  Well 0 
Gender   Moderate 15 
Female 10  Poor 9 
Male 14  Additional pathologic characteristics  
Stage   Signet ring cell 0 
I 4  Lymphatic invasion 11 
II 9  Vascular invasion 8 
III 6  
Tumor budding 12 
IV 5  
Int. J. Mol. Sci. 2014, 15 47 
 
2.1.2. Recovery of EpCAM+ Cells 
The cell recovery rate was calculated as the percentage of the EpCAM+ cell number obtained  
from immunomagnetic selection divided by the total number of cells in the suspension  
before immunomagnetic selection. The median recovery for EpCAM+ (tumor) cells was 36.9%  
(range 10.1%–94.3%; Table 2). There were no significant correlations between recovery rate of 
EpCAM positive cells with age or gender of the patients or with the clinical stage or with histologic 
features of the tumor (data not shown). 
Table 2. DNA methylation in whole tumor cell suspension (non-enriched) and in epithelial 
cell adhesion molecule (EpCAM)+ (tumor) cells (enriched). Cell recovery: Percentage of 
the EpCAM (CD326)+ cell number obtained from immunomagnetic selection divided by 
total number of cells in the tumor cell suspension before immunomagnetic selection.  
Data are expressed as Median (in brackets range). * p < 0.05 ** p < 0.01 differences 
calculated between the enriched and non-enriched samples.  
Clinical 
stage 
Recovery APC CDKN2A hMLH1 MGMT 
  Non-enriched Enriched Non-enriched Enriched Non-enriched Enriched Non-enriched Enriched 
I (n = 4) 
64.4%  
(27.3%–95.3%) 
13.7%  
(2.1%–31.0%) 
15.3%  
(1.8%–30.7%)
4.1%  
(2.0%–50.4%)
5.1%  
(0%–54.7%)
1.2%  
(0.7%–1.4%)
0.7%  
(0.5%–2.1%) 
64.4%  
(49.9%–78.3%)
67.4%  
(53.4%–83.6%)
II (n = 9) 
36.5%  
(10.1%–70.0%) 
5.2%  
(2.1%–33.8%) 
11%  
(2.4%–38.9%)
1.8%  
(0.8%–12.3%)
1.8%  
(0.7%–11.3%)
1.7%  
(0.3%–64.7%)
1.5%  
(0.6%–79.6%) 
53.1%  
(36.6%–76.7%)
59.0% *  
(36.4%–86.6%)
III (n = 6) 
36.1%  
(18.9%–64.2%) 
2.5%  
(2.0%–14.5%) 
2.7%  
(2.3%–19.9%)
1.1%  
(1.0%–1.9%)
1.4%  
(0.7%–2.1%)
1.6%  
(0.7%–3.7%)
1.8%  
(0.6%–4.8%) 
50.4%  
(24.2%–76.9%)
53.5% **  
(26.6%–77.3%)
IV (n = 4) 
38.1%  
(27.3%–67.7%) 
23.8%  
(1.8%–55.6%) 
28.8%  
(1.2%–60.6%)
1.8%  
(0.5%–3.4%)
1.5%  
(0.7%–3.8%)
1.5%  
(0.5%–61.8%)
1.2%  
(0.6%–66.4%) 
57.4%  
(34.4%–76.2%)
64.9%  
(34.2%–78.6%)
2.1.3. DNA Methylation 
The methylation of specific CpG sites (4–7 sites per gene) within the promoter regions of all  
four genes (APC, CDKN2A, hMLH1, MGMT) was quantified by pyrosequencing. To avoid potential 
confounding, both cell samples (EpCAM enriched and non-enriched cell populations) for each patient 
were processed and analyzed simultaneously (Figure 1). As expected, there were considerable 
differences in CpG methylation among genes (highest for MGMT and lowest for CDKN2A). For APC, 
the % methylation increased slightly from CpG 1 to CpG 4. Averaged across all 4 CpG sites, there was 
no significant difference in % methylation between EpCAM enriched and non-enriched cell 
populations (15.9% ± 18.2% and 14.6% ± 16.4% respectively). However, there was significantly 
higher methylation at CpG sites 3 and 4 for the enriched samples than the non-enriched ones  
(15.9% ± 18.5% and 18.5% ± 20.7% versus 14.2% ± 16.7% and 16.7% ± 18.7%, respectively;  
p < 0.05). 
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Figure 1. Comparison of the DNA methylation status between EpCAM non-enriched and 
enriched samples. Methylation of each gene (Average) and of the individual CpG sites was 
evaluated in 24 CRC patients. The bars represent the mean of the methylation values of 
each subject analyzed ± the S.E.M. Dark bars indicate EpCAM-enriched samples. 
Significant differences are indicated: * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
Methylation of the CDKN2A promoter was relatively low (4%–6%) and at each of the seven  
CpG sites analyzed there were no significant differences between the EpCAM-enriched and  
non-enriched samples.  
Similarly, for the five CpG sites interrogated within the hMLH1 promoter there were no significant 
differences in methylation for the EpCAM+ cells compared with the whole tumor cell suspension.  
The MGMT promoter was heavily methylated at all CpG sites in all patients and we observed 
significantly higher methylation in EpCAM enriched samples compared with the corresponding  
non-enriched samples. This effect was evident at each of the seven CpG sites individually and for the 
mean across all seven sites (mean methylation was 58.5% ± 17.8%, range: 26.6%–86.6% versus  
54.7% ± 16.0%, range: 24.2%–78.3%; p = 0.0002 for EpCAM+ and non-enriched cell fractions, 
respectively (Figure 1).  
Using mean data for all CpG sites within each gene promoter, Table 2 compares the methylation 
percentages of both enriched and not enriched samples for each of the 4 gene promoters in relation to 
the clinical stage. There were significant differences in methylation content between the enriched and 
the non-enriched samples only for tumors in stages II and III for the MGMT promoter (58.4% ± 17.6% 
versus 54.2% ± 14.4%, p < 0.05 and 50.4% ± 18.3% versus 47.8% ± 19.1%, p < 0.01, respectively). 
Int. J. Mol. Sci. 2014, 15 49 
 
Correlation coefficients between enriched and non-enriched cell fractions were high for methylation 
of APC, MGMT and CDKN2A genes (Spearman r = 0.83, 0.97 and 0.75, respectively; p < 0.0001) and 
moderate for hMLH1 gene (Spearman r = 0.57, p = 0.0033) (Figure 2). 
Figure 2. Correlation between the methylation values of the enriched and non-enriched 
samples. The panels represent the average percent methylation for all CpG loci analyzed in 
non-enriched (X axis) and in enriched samples (Y axis). Spearman’s correlation coefficients 
and p-values are shown. 
  
Finally, we investigated the possibility that the methylation differences between the enriched and 
the non-enriched samples might be correlated with EpCAM+ cell recovery (Figure 3). We found no 
convincing relationships for any of the four genes. However, for hMLH1, there was a weak, but 
significant, correlation (Spearman r = 0.42; p = 0.04). This apparent relationship for the hMLH1 gene 
only depended heavily on just one tumor specimen displaying high methylation content with little 
evidence of any relationship for any of the other samples. The outlier was a tumor characterized by 
high necrotic component (patient in stage II); indeed, after removal of the sample data assumed a 
normal distribution and there was no significant correlation (Pearson r = 0.18; p > 0.05). 
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Figure 3. Correlation between cell recovery and values obtained by the difference in DNA 
methylation between the enriched and non-enriched cell fractions. Tumor cell recovery  
(X axis) was obtained by the ratio between the EpCAM positive fraction and the whole 
tumor sample. Δ methylation (Y axis) represents the values obtained by the difference in 
average percent methylation for all CpG loci analyzed between the EpCAM-enriched and 
non-enriched samples. Spearman’s correlation coefficients and p-values are shown. 
 
2.2. Discussion 
DNA methylation is one of the most widely studied epigenetic marks in CRC and there is 
increasing interest in the identification and characterization of epigenetic signatures for CRC 
diagnosis, staging, tendency to metastasis, prognosis, and response to treatment [8,19]. However, 
resected CRC specimens are heterogeneous and include areas of non-malignant mucosal and 
connective tissue [20]. Given the differences in methylation between cell and tissue types [21], it is 
possible that the inclusion of stromal and other cells within a whole resected tumor specimen might 
confound analysis of the methylation content of the CRC tumor cells. This could be a particular 
problem for tumor suppressor genes which are usually unmethylated in normal tissue but can be 
heavily methylated in tumor cells. Since the percentages of stroma versus tumor epithelium vary 
widely among patients, this high degree of heterogeneity could add further complexity to comparisons 
of different tumor samples [22].  
Immunomagnetic cell sorting using a tumor-specific antibody might overcome these problems by 
providing a more homogeneous sample of cells [23,24]. 
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The epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein only expressed in 
epithelium and neoplasias derived from epithelia. It was first described as a dominant antigen in 
human colon carcinoma due to its strong expression in colon adenocarcinoma (close to 100%). 
In this work, we tested the hypothesis that EpCAM tumor cell enrichment of the CRC resected 
specimens would provide better estimates of the methylation of tumor-related genes in the  
sample compared with analysis of whole specimen. By comparing the methylation profile of the 
EpCAM+ enriched fraction with the non-enriched fraction from the same resected human CRC 
specimens, we showed that significant differences were obtained for all the CpG sites within the 
promoter region of MGMT—a gene showing high methylation values in our cohort. In addition, we 
observed significant differences also for 2 out of 4 CpG islands in the promoter of the APC gene  
(CpG site 3 and 4). When averaged across all CpG sites investigated, only the MGMT promoter region 
showed significant differences in methylation between the EpCAM-enriched and non-enriched cell 
fractions. By contrast, there were no average methylation differences between the two cell fractions for 
the other three genes that we investigated. Moreover, we did not detect convincing relationships 
between the EpCAM+ cell recovery and the difference in DNA methylation between the enriched and 
non-enriched cell fractions.  
Present results, albeit obtained by means of the analysis of only four genes in a relatively small 
group of CRC patients, suggest that also low amounts of gene promoter methylation can be detected 
either with or without EpCAM tumor cell enrichment; however, the analysis of the EpCAM enriched 
cell fraction provides a more accurate value of gene methylation than the analysis of the whole DNA 
sample, particularly in the case of high levels of promoter methylation such as those observed for 
MGMT or APC CpG site 3 and 4. Therefore, as DNA methylation percentage from EpCAM enriched 
samples is more specific for tumor methylation than that obtained from non-enriched samples, we 
believe that this procedure represents a valuable approach for the investigation of the “tumoral target”, 
and particularly in those circumnstances where the tumoral component is supposed to be relatively 
lower than the non-tumoral one, or if a precise value of methylation is required for diagnostic, research 
or therapeutic purposes. 
EpCAM may thus be an ideal tumor antigen candidate to detect circulating and metastasizing 
cancer cells. Although methylation of cancer-related genes is recognized as a promising biomarker for 
early detection and prognosis estimation [25,26], it has been scarcely investigated in Circulating 
Tumor Cells (CTCs). Recently, Chimonidou et al. demonstrated that DNA methylation of tumor 
suppressor and metastasis suppressor genes exists in CTCs [25]. 
As EpCAM is also abundantly expressed in cancer stem cells [18,27,28] it might be an ideal  
tumor antigen candidate to detect circulating and metastasizing cancer cells by immunomagnetic 
sorting [18,29,30], useful to elucidate the interplay between epigenetic gene silencing and other 
tumorigenic processes in CTCs for the understanding of tumor evolution and metastasis. 
Additionally, reliable detection of micrometastatic cells in the sentinel lymph node is a subject of 
great clinical interest, and several different protocols aimed to identify epithelial cells within the 
lymphatic basin are currently in use in breast cancer. As these cells may exist in low concentrations, 
their identification and isolation represents a difficult task [23]. 
Therefore, we think that the effort to apply this expensive and laborious procedure can be employed 
in selected experimental settings, particularly in the investigation of the CTCs: The study of 
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methylation profile of the enriched CTCs may add a new dimension to the malignant nature and 
metastatic potential of these cells. 
3. Experimental Section 
3.1. Tissue Samples 
Colorectal tissue samples were collected, with informed consent, from 26 Italian patients 
undergoing curative bowel resection at the Cisanello Hospital (Department of Surgery, Medical, 
Molecular, and Critical Area Pathology, University of Pisa, Pisa, Italy). Individuals who met the study 
eligibility criteria and provided written informed consent were enrolled. None of the patients received 
preoperative chemotherapy or radiotherapy.  
The study was performed according to the principles of the Declaration of Helsinki and was 
approved by the Clinical Research Ethics Committee of the Pisa University Hospital. 
All samples were evaluated and diagnosed histologically by an expert pathologist, and 
representative tissue sections were selected for DNA extraction and further molecular analyses. 
3.2. Generation of a Single Cell Suspension from Colorectal Cancer Tissues 
Cells were derived from biopsies as previously described [31]. After resection, intestinal tissue was 
cut lengthwise, deeply into the submucosal layer, avoiding fistulas and necrosis. After extensive 
washing with saline solution, the fragments were dissected into wedge-shaped pieces and immediately 
placed in a sterile container containing a basic transport medium (RPMI; Gibco Laboratories, Grand Island, 
NE, USA). Tumor samples were washed in RPMI medium supplemented with concentrated  
antibiotics (penicillin (500 U/mL), streptomycin (500 μg/mL), gentamicin (100 μg/mL), amphotericin B  
(12.5 μg/mL) and metronidazole (5 μg/mL)) and then minced with a medical scalpel into 0.5–2.0 mm3 
fragments excluding macroscopic excess fat and necrotic tissues. Fragments were immediately 
enzymatically digested with 5–10 mL of bovine collagenase type H (Sigma-Aldrich, Dublin, Ireland) 
at a concentration of 1.5 mg/mL and shaken by an agitator for about 6 h at 37 °C. Successful 
enzymatic digestion was assessed by examining an aliquot of the cell suspension under an inverted 
microscope. The suspension was then filtered through a double layer of sterile gauze and washed with 
medium containing foetal bovine serum to inactivate collagenase. 
Cell viability was assessed by the trypan blue dye exclusion method and the number of cells was 
determined by hemocytometer counting. 
Each cell suspension was divided into two aliquots: one was immediately stored at −20 °C until 
processing and the other one was used for the tumor cell enrichment procedure. 
3.3. Tumor Cell Enrichment with Anti-EpCAM Antibodies 
Tumor cells were isolated from the cell suspensions obtained as described above using 
immunomagnetic beads coated with anti-EpCAM (CD326) antibodies using the manufacturer’s 
protocol (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). 
Briefly, the cell suspension was diluted with buffer (0.5% foetal calf serum, 2 mM ethylenediamine 
tetraacetic acid (EDTA) in phosphate buffered saline (PBS), pH 7.2) and incubated with the  
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anti-EpCAM antibody-loaded microbeads for 30 min at 2–8 °C, then washed with buffer solution. 
Then the cell suspension was transferred to a column placed in the magnetic field of a MACS 
Separator (Miltenyi Biotec, Bergisch Gladbach, Germany). This allowed separation of the 
magnetically labeled CD326+ cells which were retained on the column whilst the unlabeled cells 
(CD326−) ran through the column. The column was then removed from the magnetic field and the 
CD326+ cells were eluted and collected. The recovered CD326+ cells were enumerated and 
maintained at −20 °C. Tumor cell recovery was calculated as percentage of the CD326+ (EpCAM) cell 
number obtained from immunomagnetic selection divided by total number of cells in the tumor cell 
suspension before immunomagnetic selection.  
3.4. Extraction of Genomic DNA 
Genomic DNA was extracted using the QIAmp DNA blood Mini Kit (Qiagen, Milan, Italy) 
according to the manufacturer’s instruction. The extracted DNA was quantified using a Nano Drop ND 
2000c spectrophotometer (NanoDrop Thermo scientific, Wilmington, DE, USA).  
3.5. Bisulfite Modification 
Sodium bisulfite modification was performed using the EZ DNA MethylationGold Kite  
(Zymo Research, Orange, CA, USA), according to the manufacturer’s instructions. Bisulfite-treated 
DNA was eluted in 10 μL of elution buffer. 
3.6. Pyrosequencing 
DNA methylation was measured performing the amplification of bisulfite modified DNA, followed 
by pyrosequencing. Genomatix software (http://www.genomatix.de) Gene2Promoter was employed to 
identify the promoter regions of interest and PSQ Assay Design software (Biotage, Uppsala, Sweden) 
was used to design the corresponding primer sets. Bisulfite modified (BM) 0% and 100% methylated 
DNA were diluted to produce DNA mixtures with defined methylation content (0%, 25%, 50%, 75%, 
100%) which were used subsequently for PCR and pyrosequencing validation. The standard conditions 
for the PyroPCR were: 12.5 µL Taq Mastermix (Qiagen, Milan, Italy), 10 pmol of each primer and  
50 ng of BM DNA in a total volume of 25 µL. The PyroPCR temperature profile was the following:  
95 °C for 15 min, 94 °C for 15 s, Ta for 30 s, 72 °C for 30 s (Repeat steps 2, 3, 4 × 50 times) and 72 °C 
for 10 min. Table 3 shows the pyrosequencing conditions (primers, annealing temperature and  
CpG sites analyzed) for the studied genes (CDKN2A, APC, MGMT and hMLH1). Pyrosequencing was 
performed at the Human Nutrition Research Centre, Institute for Ageing & Health, Newcastle 
University, Newcastle upon Tyne, UK. A fully methylated and non-methylated control DNA was 
included in each run to verify the validity of pyrosequencing results. Methylation sensitive-high 
resolution melting technique (MS-HRM) was performed in a subgroup of 10 subjects to validate 
pyrosequencing data (Details on the comparison of pyrosequencing and MS-HRM for APC and 
CDKN2A genes can be found in reference [19]). 
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Table 3. Pyrosequencing conditions and analyzed sequences. 
Genes  Primer pyrosequencing Ta RefSeqGene CpG sites analyzed 
APC 
F-TATTAATTTTTTTGTTTGTTGGGGA 
55 °C NG_008481.4
C/TGGAGTGC/TGGGTC/TGGGAAGC/TGG 
R-AACTACACCAATACAACCACATATC AGAGAGAAGTAGTTGTGTAATTC/TGTTG 
Sequencing primer: 
GGGGTTTTGTGTTTTATTG 
GATGC/TGGATTAGGGC/TGT 
CDKN2A 
F-AGAGGATTTGAGGGATAG 
50 °C NG_007485.1
GAGGGTGGGGC/TGGATC/TGC/TGTGC/TG 
R-AATTCCCCTACAAACTTC TTC/TGGC/TGGTTGC/TGGAGAGGGGGAGAGT 
Sequencing primer: GGGTTGGTTGGTTATTA AGGTAGC/TGGGC/TGGC/TG 
hMLH1 
F-GGTTATAAGAGTAGGGTTAA 
45 °C NG_007109.2
TTC/TGTATTTTTC/TGAGTTTTTAAAAAC/TGA 
R-ATACCAATCAAATTTCTC ATTAATAGGAAGAGC/TGGATAGC/TGATTTTT
Sequencing primer: 
TGTTTTTATTGGTTGGATAT 
AAC/TGC/TGTAAGC/TGTA 
MGMT 
F-AGTTTTTTTGGTGGATATA 
47 °C NP_002403.2
TC/TGC/TGTTTC/TGGGTTTAGC/TGTAGTC/TGT
R-TACCTTTTCCTATCACAA 
TTC/TGAGTAGGATC/TGGGATTTTTATTAAG 
Sequencing primer: TTTAGGAGGGGAGAGAT
3.7. Statistics 
All numerical data were expressed as mean, and the standard deviation (SD) was calculated. The 
data from EpCAM-enriched and non-enriched cell fractions were compared using Student’s t test  
(for continuous, normally distributed data) or Wilcoxon signed-rank test (for non-normally distributed 
paired data). Two-tailed p-values were considered statistically significant at p < 0.05. Statistical testing 
was carried out using GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA, USA). 
4. Conclusions 
Tumor cell tissue separation using immunomagnetic beads is relatively expensive and  
time-consuming. However, our findings suggest that, in some cases, it could give a more accurate 
value of gene promoter methylation than the analysis of the whole cancer tissue, and might therefore 
be of value in those circumstances where the tumoral component is supposed to be lower than the  
non-tumoral one. 
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